Lonza's 2026 Txoj kev npaj: Cov lus nug rau cov neeg yuav Peptide CDMO

Tus CEO ntawm Lonza tau hais dab tsi txog kev sib tw muaj peev xwm CDMO?

Peptides Factory Wholesale Teduglutide Lonza's Capital Markets Day tau hais txog kev ntxiv peev xwm los txhawb nws txoj kev loj hlob uas xav tau thiab nrhiav txiaj ntsig los ntawm peev xwm. Qhov no yog txoj kev tswj hwm tau hais, tsis yog pov thawj tias peev xwm tsim peptide yog txaus rau txhua tus.

Nyeem ob nrab ua ke thiab qhov chaw yog sib haum xeeb tsis yog sib cav. Lub tuam txhab tseem yuav ntxiv peev xwm; nws tsuas yog tsis ntxiv kom yeej kev sib tw ntim. Qhov nws xav tau them yog peev xwm uas puag ncig molecule, uas yog tib qho kev hloov uas kev nthuav dav DNA-rau-IND qhia txog: kev xa khoom ntev dua ib qho kev pab cuam es tsis yog ntau litres ib xyoos.

Ib qho cim scope ua ntej koj siv qhov no rau peptides. Hauv tib lub rooj sib tham CEO piav txog 'kev tsis txaus txuas ntxiv', high and too high utilization of the globally available capacity” for mammalian capacity. That is a cell-culture observation, not a statement about peptide API. The strategic posture transfers to peptide buying; the utilization remark does not.

Is the peptide CDMO industry really done adding capacity?

Capacity remains relevant, alongside technical fit and quality. One company’s strategic statement does not establish that capacity has ceased to differentiate suppliers across the sector.

The two best public indicators point in different directions because they measure different things. One provider’s 2025 industry survey reports that average annual growth in operating capacity slipped by 1.0% for mammalian and 0.9% for microbial production, as new suites came online faster than pipelines could fill them, while CDMO service sales grew 17.1% a year. The peptide CDMO market forecast puts the peptide CDMO market at USD 2.1 billion in 2025, USD 2.3 billion in 2026 and USD 5.0 billion by 2033, an 11.7% compound annual growth rate.

The apparent contradiction dissolves once you name the units. One provider’s survey measures the direction of capacity utilization in cell-culture platforms. Grand View models revenue in a different modality. Neither is a peptide capacity utilization figure, and we would not print one as if it were. What both support is a single buyer-facing conclusion: the supply base is expanding, so a supplier’s willingness to build square metres tells you almost nothing about whether it can make your molecule.

Ceeb toom No public figure in these sources gives peptide-specific capacity or utilization. Treat any supplier presentation that quotes one without a methodology as marketing.

The criterion to carry forward: ask what the added capacity is configured to do, not how much of it there is.

Why is production volume the wrong yardstick for complex peptide programs?

Because the failure modes that hurt you are chemical, and volume does not address them. A supplier can have all the reactor litres in the world and still return a batch where your peptide is not the majority species.

The base rates are sobering. An analysis of roughly 1,800 synthesised sequences found that 3.6% of syntheses showed no or minor signal for the desired peptide, a complete failure, and that in 14% of cases the ordered peptide was not the majority of the peptide mass. Tsis yog 87% met a threshold of more than 50% abundance. That is research-grade, high-throughput material, not API, but it establishes the shape of the risk: difficult sequences fail at a rate you cannot average away with more capacity.

Conventional SPPS is not generally limited to 15–20 residues. Sequence, route, scale and purification determine feasibility; both longer successes and difficult short sequences are possible.

Pro Tip The EU guideline’s impurity thresholds and the 50%-abundance criterion measure different things. A batch can fail the abundance test while every individual impurity sits below the 1.0% qualification threshold. Do not let a supplier answer one with the other.

For an aggregation-prone 40-mer with two disulfide bonds, the questions that decide the program are about coupling strategy, kev tswj hwm kev txwv, kev tswj oxidation thiab kev daws teeb meem tshuaj ntsuam. Tsis muaj ib qho ntawm lawv tshwm sim hauv daim ntawv muaj peev xwm.

What does fit-for-purpose CDMO capability include, step by step?

Kev haum rau lub hom phiaj yog ib qho kev sib koom ua ke, tsis yog ib daim ntawv teev cov haujlwm unit. Kev kuaj yog seb tus neeg muab khoom puas tuaj yeem coj koj los ntawm kev xaiv txoj kev mus txog kev kuaj tso tawm raws li ib qho kev tswj hwm, nrog cov txheej txheem tshuaj ntsuam tsim rau cov impurities uas tshuaj lom neeg tiag tiag tsim.

Pib nrog yam uas specification yuav tsum muaj. Cov kev kuaj specification uas EU cov lus qhia xav tau suav nrog kev txheeb xyuas, tag nrho thiab tus kheej huv, cov hom molecular-weight siab los ntawm SEC-LC nrog cov hom uas tau npe (dimers, Trimers, oligomers, aggregates, vim tias kab 'HMW impurities' generic tsis raug lees txais), assay, counter-ion identity and content, residual TFA, dej, residual solvents, elemental impurities, bacterial endotoxins thiab microbiological purity.

Then ask how the process controls what those tests will find. The impurity origins the guideline names include deletion and truncated sequences from incomplete coupling and capping, insertion sequences, epimerisation, cleavage-related substances, and degradation routes such as oxidation, deamidation, aspartimide formation, diketopiperazine and pyroglutamic acid formation.

u, ask how the methods were validated. ICH Q2(R2), adopted in November 2023, ties validation characteristics to analytical purpose: specificity, working range, kev raug thiab qhov tseeb, with robustness established during development.

Nov yog qhov zoo li cas ntawm ib lub saw sib koom ua ke hauv kev ua haujlwm. Peb pab pawg khiav solid-phase, liquid-phase, kev sib xyaw ua ke-liquid-solid thiab inverse solid-phase synthesis nrog microbial fermentation, los ntawm milligram mus rau kilogram scale, nrog purity los ntawm crude mus rau 99%, TFA ua tus counter-ion thiab acetate default, chloride lossis ammonium sib pauv muaj. Kev kuaj tso tawm npog MS rau kev txheeb xyuas thiab HPLC rau kev huv, nrog endotoxin, cov ntsiab lus tiv thaiv ion, bioburden, x, kev lees paub noo thiab kev txheeb xyuas kab ke muaj raws li xav tau, thiab kev tsim khoom khiav los ntawm kev tsim mus rau kev npaj HPLC thiab lyophilization hauv ib pawg 100 chav huv.

How do you compare peptide suppliers on evidence rather than claims?

Koj piv lawv ntawm cov ntaub ntawv uas sib piv ib leeg. ib qho kev thov ntawm tus neeg muab khoom yog ib kab lus; a supplier’s evidence is a lot number that leads to a chromatogram, which leads to a validated method, which leads to a stability protocol. When we assess a peptide CDMO selection file, that chain is what we test first, because lot-to-lot consistency cannot be verified from a stack of unattached PDFs.

The regulatory baseline has moved, and that changes what you should request. The EU synthetic-peptide guideline in force since June 2026 sets peptide-related impurity thresholds at 0.1% reporting, 0.5% identification and 1.0% qualification, because synthetic peptides sit outside ICH Q3A. Methods must be sensitive enough to meet that 0.1% reporting threshold, and where impurities co-elute the 1.0% qualification threshold applies unless justified.

For process changes, know which framework you are borrowing. The comparability expectations in ICH Q5E require analytical evidence that a change has no adverse impact on quality, safety or efficacy, but the guideline does not prescribe a fixed analytical program. It is scoped to biological products, so use its logic, not its letter, for a synthetic peptide.

Qhov tseem ceeb A usable data package cross-references lot to chromatogram to method to stability protocol. If any link is missing, you cannot verify lot-to-lot consistency, and the claim is unverified.

Where does scale-up from mg to kg actually break down?

Scale-up can change mixing, mass transfer, impurity profiles and purification needs. An analytical method is qualified for its purpose and sample matrix, not simply a milligram or kilogram batch label; assess whether changed material remains within demonstrated coverage.

The mass data make the mechanism visible. Peptide manufacturing’s material intensity reports process mass intensity for commercial and Phase 3 solid-phase processes ranging from 1,684 to 34,585 kg of waste per kg of product, averaging about 13,063 for peptides of 6 to 43 residues, with downstream processing accounting for roughly 50% of that intensity because of dilute product solutions and long chromatographic gradients. The same analysis puts liquid-phase processes at an average of about 3,984, against roughly 8,300 for biopharmaceuticals and 168 to 308 for small molecules.

The practical reading is not that solid-phase is bad. It is that route choice is a scale-up decision, and a supplier who cannot discuss liquid-phase or hybrid options for a long or difficult sequence has a narrower toolkit than your program may need. The same analysis notes that mass intensity per amino acid stays essentially static across development phases for solid-phase processes, which means the inefficiency does not fix itself as you advance.

Ceeb toom No peer-reviewed figure quantifies mg-to-kg yield loss for a specific peptide. Judge scale-up readiness from the mechanism and from the supplier’s own lot history, not from a quoted percentage.

What belongs on a peptide CDMO shortlist scorecard?

Weight capability above capacity, and make capacity a single line rather than the headline. That is the practical translation of a value-capture posture into a buying decision.

Compare each supplier’s relevant capability, quality system, capacity and continuity evidence. Large providers and specialists vary; neither type has a guaranteed advantage in difficult-sequence work or redundancy.

Score each line on evidence you have actually seen, not on what a business development call promised. If a supplier cannot supply the evidence for a high-weight line, that is a lower score, not a neutral one.

If you want a second opinion on where your sequence sits against these criteria, our team can review the technical package against the scorecard and tell you which evidence is missing before you commit.

Cov Lus Nug Nquag Nug

Does Lonza’s capacity statement actually apply to peptides?

The strategic posture does; the utilization data does not. The remarks about undersupply concerned mammalian capacity, not peptide API, so treat the “value capture” framing as a signal about how large CDMOs are positioning themselves, and evaluate peptide CDMO selection on peptide-specific evidence instead.

Can a specialist supplier carry a program from mg to kg?

Often yes, and for difficult sequences it can be the better choice. What decides the transfer is the route and the analytics, not the reactor volume: ask for lot history across the scale range, method transfer records and a named route strategy for your sequence. A specialist that shows you the transfer data is a stronger bet than an integrated provider that shows you a capacity chart.

My program is mid-transfer with a thin data package. What should I request first?

Request relevant chromatograms and validation summaries, then review identity, content, kev ruaj ntseg, process and quality records as needed. Two document types cannot verify every aspect of a supplier or lot.

Did the July 2026 FDA withdrawal change what I should ask for?

It raises the value of regulatory awareness as a selection criterion. Ask which guidance version a supplier is working from and how it has changed their impurity and characterization work, then confirm the applicable requirements with your own regulatory function before you rely on any of it in a filing.

Xaus lus

The capacity race framing was always a proxy. What a peptide program actually needs is a supplier that can make a difficult sequence, prove what it made, and carry both the process and the analytical package through scale-up without the evidence thinning out. One provider’s CEO said the company is in a value capture race, and for buyers that is a useful prompt: stop scoring suppliers on tonnage and start scoring them on the documents they can put in front of you.

The takeaway is a working method, not a verdict. Weight difficult-sequence track record, analytical depth and route flexibility above capacity. Demand that every lot number lead to a chromatogram, a validated method and a stability protocol. Treat a missing link as a red flag rather than a gap to be filled later. And check that the regulatory baseline your supplier cites is the one currently in force, not the one that was withdrawn.

Score your current shortlist against the table above, line by line, on evidence you have seen. Where a high-weight line has no evidence behind it, request it before the next round of discussions, and let the answers decide the ranking. If you would like our team to review your sequence and the package you have collected so far, get in touch with your requirements and we will tell you what is missing.

Xiaoxia Chen

New Drug R&D Technician Kev txawj ntse tseem ceeb: Kev tshawb nrhiav lub hom phiaj, kev sib raug zoo ntawm qauv thiab kev ua haujlwm (SAR) kev tshuaj xyuas, peptide-drug conjugates (PDCs), and the development of anti-aging and metabolic peptides.

Hais txog tus sau Cov ntawv tshiab tshaj plaws

Profile: Xiaoxia Chen has led the early discovery and preclinical research for several metabolic and tumor-targeted peptide drugs. She is not only proficient in high-throughput screening of peptide libraries but also skilled in utilizing AI-assisted computational biology for de novo peptide sequence design. Currently, Nws tab tom coj ib pab neeg tshwj xeeb rau kev tshawb fawb tob thiab kev tsim kho tshiab ntawm cov tshuaj ua haujlwm ntau yam tshiab (xws li ob leeg- lossis peb hom hom peptides txo rog) thiab cov peptides kho cov ntaub so ntswg muaj zog heev.

• Proteoform Metrics rau kev txheeb xyuas peptide: Ntawm kev huv ntawm sequence 2026年11月1日
• Retatrutide and the GLP-1 Grey Market: Why Peptide Identity Is Only the Starting Point 2026年10月31日
• Six Peptides Recommended: What the July 2026 Advisory Votes Mean for Evidence Readiness 2026年10月31日
• s $3 Billion Biotech Fund Signal: Where Peptide Platform Capabilities Fit in the Next Capital Cycle 2026年10月31日
• Lonza's 2026 Txoj kev npaj: Cov lus nug rau cov neeg yuav Peptide CDMO 2026年10月29日

Fact Checked & Editorial Guidelines

Our Fact Checking Process

Peb muab qhov tseeb thiab kev ncaj ncees rau peb cov ntsiab lus. Nov yog peb txoj kev khaws cia cov qauv siab:

1. Kev tshuaj xyuas los ntawm cov kws tshaj lij: Tag nrho cov ntawv raug tshuaj xyuas los ntawm cov kws tshaj lij hauv lub ntsiab lus.
2. Kev txheeb xyuas qhov chaw: Cov ntaub ntawv muaj kev ntseeg tau, cov chaw tshiab tshaj plaws.
3. Kev pom tseeb: Peb qhia meej txog cov ntaub ntawv thiab qhia txog tej kev tsis sib haum xeeb.

Tau tshuaj xyuas los ntawm: Cov kws tshaj lij hauv lub ntsiab lus

Peb Pawg Saib Xyuas

Peb cov ntsiab lus raug tshuaj xyuas zoo los ntawm cov kws tshaj lij muaj kev paub kom paub tseeb tias muaj tseeb thiab muaj feem xyuam.

• Cov kws tshaj lij muaj txuj ci: Txhua tsab ntawv raug tshuaj xyuas los ntawm cov kws tshaj lij uas muaj kev paub tshwj xeeb hauv thaj chaw.
• Cov ntaub ntawv tshiab tshaj plaws: Peb suav nrog cov kev tshawb fawb tshiab tshaj plaws, cov kev hloov tshiab, thiab cov qauv.
• Kev cog lus rau qhov zoo: Cov neeg tshuaj xyuas xyuas kom meej meej, kev raug, thiab tag nrho.

Nrhiav lub npe tshuaj xyuas los ntawm cov kws tshaj lij kom nyeem cov ntsiab lus uas koj tuaj yeem ntseeg tau.